HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial.
(2026 Jul 13)
Lancet HIV
Bekker LG, Moodley D, Diallo DD, Harkoo I, Kigozi G, Kiwanuka N, Louw CE, Malahleha M, Mworeko L, Palanee-Phillips T, Panchia R, Singh N, Puryear SB, Arora P, Baeten JM, Brown A, Carter CC, Imperial M, Ling J, Singh R, Wong P, Das M, Kiweewa FM

Integrating oral pre-exposure prophylaxis delivery in primary care family planning clinics: a pragmatic, stepped-wedge, cluster-randomised trial.
(2025 Nov)
Lancet Prim Care 1(5):
Mugwanya KK, Matemo D, Meisner A, Schaafsma T, Morton J, Wandera C, Kemunto V, Cherotich I, Odhiambo S, Bii M, Oduor B, Achieng E, Oyombra T, Owaga D, Beima-Sofie KM, Baeten JM, Kinuthia J

Effect of enhanced peer PrEP referral with HIV self-testing delivery among young Kenyan women: A randomized controlled trial of peer networks.
(2026 Mar)
PLoS Med 23(3): e1005023
Ortblad KF, Wairimu N, Culquichicon C, Njeru I, Malen RC, Reedy AM, Ekwunife O, McGowan M, Mwangi M, Muthoni A, Kiboi D, Njoroge S, Gao F, Baeten JM, Ngure K

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.
(2026 Mar)
Lancet Microbe 7(3): 101283
Ogbuagu O, Gaur A, McMahon JH, Gorgos L, Morales-Ramirez JO, Workowski K, Brunetta J, Mponponsuo K, Collins SE, VanderVeen LA, Zhang N, Huang H, Baeten JM, Eron J

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
(2026 Feb)
Ann Intern Med 179(2): 168-176
Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, Dretler AW, Nahass RG, Sinclair GI, Berhe M, Roberts A, Applin S, Brinson C, Jayaweera D, Workowski KA, Shihadeh F, Liu SY, Klopfer S, Llamoso C, Madera S, Dvory-Sobol H, Rhee MS, Rhee EG, Baeten JM, Eron JJ